help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Remacle-Bonnet, M. M.
Right arrow Articles by Pommier, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remacle-Bonnet, M. M.
Right arrow Articles by Pommier, G. J.

Journal of Clinical Endocrinology & Metabolism, Vol 75, 609-616, Copyright © 1992 by Endocrine Society

ARTICLES

Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line

MM Remacle-Bonnet, JM Culouscou, FL Garrouste, C Rabenandrasana, JL Marvaldi and GJ Pommier
Laboratoire d'Immunopathologie, Faculte de Medecine, Marseille, 3, France.

The HT29 human colonic carcinoma cell line secretes insulin-like growth factor (IGF)-II. We have examined these cells for expression of IGF receptors. Competitive binding assays as affinity cross-linking experiments using 125I-IGF-II fail to reveal type II IGF receptors at the cell surface. In contrast, cross-linking studies with either 125I- IGF-I or 125I-IGF-II reveal an M(r) 135,000 protein that follows a peptide binding specificity characteristic of the alpha-subunit of the type I IGF receptor. However, 125I-IGF-II binding to this receptor is not inhibited at 4 C by alpha IR-3, a monoclonal antibody to the type I IGF receptor. Analysis of the competitive binding curves with each one of these radioligands suggests that HT29 cells express both a classical type I IGF receptor (about 6,000/cell; KdIGF-I = 0.48 nmol) and a variant one whose 125I-IGF-II binding is not blocked by alpha IR-3 (about 15,000/cell; KdIGF-II = 4.0 nmol). Endocytosis studies of specific cell-bound 125I-IGF-I or 125I-IGF-II suggest that ligand interaction with the classical, but not the variant, binding site is only able to induce receptor internalization. An identical IGF receptors pattern is observed with HT29-D4 clonal cells induced to differentiate by culture in a glucose-free medium.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. Zhao, M. Berho, J. Nogueras, D. Sands, E. Weiss, S. Wexner, F. M. Giardiello, and M. Cruz-Correa
Positive Correlation of Insulin-Like Growth Factor-II with Proliferating Cell Index in Patients with Colorectal Neoplasia
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1819 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
A. M. Y. Nomura, G. N. Stemmermann, J. Lee, and M. N. Pollak
Serum Insulin-like Growth Factor I and Subsequent Risk of Colorectal Cancer among Japanese-American Men
Am. J. Epidemiol., September 1, 2003; 158(5): 424 - 431.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. L. Garrouste, M. M. Remacle-Bonnet, M. M.-A. Lehmann, J. L. Marvaldi, and G. J. Pommier
Up-Regulation of Insulin/Insulin-Like Growth Factor-I Hybrid Receptors during Differentiation of HT29-D4 Human Colonic Carcinoma Cells
Endocrinology, May 1, 1997; 138(5): 2021 - 2032.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society